Transcend Biologics is thrilled to share a new study from Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, investigating the use of Tropocells® PRP for treating knee osteoarthritis.
The study, titled “High Dose Neutrophil-Depleted Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Study,” reveals some impressive findings. Researchers evaluated 212 patients with Kellgren-Lawrence (KL) grade 1-3 knee osteoarthritis and found that over 70% of patients responded positively after just the first injection. These positive results were sustained through 12 months following a three-injection treatment regimen.
What’s particularly exciting is how these outcomes highlight and confirm the effectiveness and safety of Tropocells® PRP. Our PRP’s high platelet concentration and purity continue to play a crucial role in achieving such significant and lasting results. It’s clear that Tropocells® PRP is not just effective but also a reliable option for patients, providing sustained relief from osteoarthritis symptoms.
We’re proud to see Tropocells® PRP being scientifically tested and making such a difference in patient life quality. We are excited about the potential this has for enhancing your offerings.
Follow the link to download the study ➡ High Dose Neutrophil Depleted Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Study[v1] | Preprints.org
Recent Comments